We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Snibe Diagnostic Displays Analyzers at MEDLAB Europe 2018

By LabMedica International staff writers
Posted on 04 Oct 2018

Image: Snibe showcased its latest range of chemiluminescent immunoassay analyzers at MEDLAB Europe 2018 (Photo courtesy of Snibe).

Image: Snibe showcased its latest range of chemiluminescent immunoassay analyzers at MEDLAB Europe 2018 (Photo courtesy of Snibe).

Shenzhen New Industries Biomedical Engineering Co., Ltd. {(Snibe Co. Ltd.) Shenzhen, China} showcased its latest range of chemiluminescent immunoassay analyzers at MEDLAB Europe 2018 held in Barcelona, Spain, from October 2-4, 2018.

More than 150 exhibitors showcased the latest cutting edge technologies and recent developments in the medical laboratory industry at the second edition of the show. MEDLAB Europe 2018 welcomed more than 2,600 international visitors and delegates, offering international manufacturers a chance to network with over 1,000 medical dealers and distributors from Spain, Italy, France, Germany, Portugal and other countries.

Snibe is a bio-medical company specialized in clinical laboratory instruments and in vitro diagnostic reagents. The company manufactures a range of chemiluminescent immunoassay analyzers and clinical chemistry analyzers. It has achieved several milestones, such as developing China's first automated CLIA analyzer and dedicated kits in 2008 and launching the country’s first integrated system in 2012. Snibe is also the first CLIA manufacturer in China to receive FDA clearance in 2017.

Snibe offers chemiluminescent immunoassay analyzers under the MAGLUMI series and its clinical chemistry analyzers under the Biossays series. Currently, more than 3,000 hospitals in China are using the company’s MAGLUMI CLIA system. Snibe also offers the Biolumi 8000 Integrated Lab System that combines an electrolyte module, chemistry module and immunoassay module in a single platform.

Visit expo >

New

Gold Member

Pre- Eclampsia Control

Acusera Pre-Eclampsia Control

Online QC Software
Acusera 24•7

Electrolyte Analyzer

BKE-B

Clinical Informatics Platform

CLARION™

Latest MEDLAB 2018 News

Channels

Clinical Chemistry

view channel

New Machine-Learning Equation Improves LDL Cholesterol Assessment

Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more

Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms

Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read more

Graphical Abstract (Image Credit: Joohyung Park et al., Chemical Engineering Journal, 2026. DOI: 10.1016/j.cej.2026.179140)

Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood

Early diagnosis of liver fibrosis remains challenging because the condition often progresses without symptoms, while traditional assessments rely on invasive biopsy or costly imaging. Timely identification... Read more

Blood Test Improves Alzheimer’s Diagnosis Across Care Settings

Early and accurate identification of Alzheimer’s disease remains challenging in routine care, particularly outside memory clinics. Confirmation often depends on positron emission tomography (PET) imaging... Read more

Molecular Diagnostics

view channel

New Biomarker Helps Guide Combination Therapy for Treatment-Resistant Breast Cancer

Chemotherapy resistance hampers treatment of triple-negative breast cancer (TNBC), particularly in tumors with TP53 mutations. Identifying biomarkers that signal resistance while pointing to actionable... Read more

Blood-Based Gene Expression Test Detects Early Pancreatic Cancer

Pancreatic cancer remains difficult to detect at a curable stage and is associated with poor survival outcomes. In Japan, the five-year relative survival rate is 8.5%, while early-stage disease accounts... Read more

Blood-Based Biomarker Panel Outperforms Existing Liver Disease Tests

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver dysfunction, affecting about one in three adults. Diagnosis often occurs late and still relies in part... Read more

HPV Assay Gains Expanded CE Mark for Self-Collected Vaginal Samples

Cervical cancer is the fourth most common cancer in women and is largely preventable through vaccination and regular screening. However, even where organized screening programs exist, participation varies... Read more

Hematology

view channel

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

AI Decision Support System Guides Treatment Selection for Complex Blood Cancers

Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more

Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack

ST-elevation myocardial infarction (STEMI) is a severe heart attack caused by complete blockage of a coronary artery. Early risk stratification at hospital admission is challenging but essential for guiding... Read more

Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows

Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more

Immunology

view channel

New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients

Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more

Cell-Free Assay Detects Functional IgE for Food Allergy Diagnosis

Accurately distinguishing sensitization from clinically relevant food allergy remains a challenge for laboratories, as routine blood tests detect allergen-specific immunoglobulin E (IgE) but not its capacity... Read more

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more

Microbiology

view channel

Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation

U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more

Image: The addition builds on a QIAstat-Dx menu that also includes respiratory, gastrointestinal, and meningitis/encephalitis panels (Photo courtesy of Qiagen)

Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections

Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read more

Image: Graphical Abstract (Ahavi P, Hoang TN, Meyer P, et al. Cell Systems, 2026; doi:10.1016/j.cels.2026.101654)

Bacterial Growth Assay Predicts COVID-19 Severity From Plasma

COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more

Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults

Frailty in older adults is marked by increased vulnerability to disease, falls, functional decline, and death, yet its biological drivers remain incompletely understood. Because the gut microbiota influences... Read more

Pathology

view channel

Image: Atypical clustering of myeloid progenitor cells called myeloblasts (white arrows), defined by their co-expression of CD34 (magenta) and CD117 (green), in a bone marrow biopsy tissue from a patient with MDS. (Image Credit: Dr. Sanjay Patel)

AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity

Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read more

Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue

Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more

Image credit: Adobe Stock

AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer

Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read more

Image: Graphical Abstract (Yang Liu et al,. Cancer Cell (2026). DOI: 10.1016/j.ccell.2026.06.009)

Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk

Colorectal cancer remains a leading cause of cancer mortality, and many patients relapse despite apparently successful surgery and chemotherapy. Detecting minimal disease that persists after treatment... Read more

Technology

view channel

Training Device Improves Accuracy of Pooled Molecular Diagnostics

High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more

New CE-Certified Software Advances Whole-Genome Cancer Testing

European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more

National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care

Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more

AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines

Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more

Industry

view channel

Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition

Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more

Seed Amplification Test Expands Access to Neurodegenerative Disease Testing

Amprion, Inc. has secured a multi-million-dollar growth investment from Decathlon Capital Partners to expand its diagnostic testing capacity for neurodegenerative diseases. The San Diego-based company... Read more

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more

Eurobio Scientific Completes Acquisition of CareDx Lab Products Division

Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more